Basic Information
Strensiq
Regulatory Information
EMEA/H/C/003794
August 28, 2015
June 24, 2015
17
February 7, 2024
Company Information
France
103-105 rue Anatole France 92300 Levallois-Perret
Alexion Europe SAS
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.
Overview Summary
Strensiq is a medicine used long-term to treat patients with hypophosphatasia that started in childhood. Hypophosphatasia is a rare inherited disease of the bones which can lead to early loss of teeth, malformed bones, frequent bone fractures, and difficulty breathing. Strensiq contains the active substance asfotase alfa. Hypophosphatasia is rare, and Strensiq was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 3 December 2008.